



Alexander Dinur

Associate

New Jersey

T: +1 973.422.6732 | F: +1 973.597.2400

adinur@lowenstein.com

Alex's practice focuses on a broad range of capital markets, M&A, private equity, corporate governance, securities compliance, and corporate finance matters. He is experienced in drafting documentation and developing strategy for all stages of public offerings and private placements of debt and equity securities, including IPOs, follow-on offerings, and Rule 144A offerings representing underwriters, agents, and issuers.

He regularly advises clients on corporate governance and securities compliance issues, including Securities and Exchange Act reporting. Alex also drafts governance documents such as committee charters, and he prepares ancillary documents for credit facilities, private placements, and other forms of debt financing.

Alex's recent focus has been on technology and life sciences companies in the small- to mid-cap markets. In that capacity, he serves as a trusted counselor to senior management by giving thoughtful advice and attentive service.

EXPERIENCE

- > Represented Maxim Group LLC, as dealer-manager, in connection with a \$15.1 million rights offering for Actinium Pharmaceuticals, Inc. (NYSE American: ATNM).
- > Represented H.C. Wainwright & Co., LLC, as the exclusive placement agent, in connection with a \$11.25 million registered direct offering for EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG).
- > We represented H.C. Wainwright & Co., LLC, as the underwriter, in connection with a \$28.75 million public offering for Onconova Therapeutics, Inc. (Nasdaq: ONTX).
- > Represented H.C. Wainwright & Co., LLC, as underwriter, in connection with a \$10.5 million public offering for Fibrocell Science, Inc. (Nasdaq: FCSC).
- > Represented ROTH Capital Partners, as underwriter, in connection with a \$10 million public offering for Myomo, Inc. (NYSEAMERICAN: MYO).
- > Represented Cancer Genetics, Inc. (Nasdaq: CGIX) in connection with its \$7 million registered direct offering.
- > Represented Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) in a \$32.6 million public offering.
- > Represented DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) in its \$10 million registered direct offering.
- > Represented Laidlaw & Company (UK) Ltd., as placement agent, in connection with a registered direct offering for MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX).
- > Represented Cancer Genetics, Inc. (Nasdaq: CGIX) in connection with its \$12 million acquisition of vivoPharm Pty. Ltd.
- > Represented Cancer Genetics Inc. (Nasdaq: CGIX) in its \$16 million registered direct offering of common stock to Aspire Capital Fund LLC.

NEWS & INSIGHTS

Publications

- > July 16, 2020
"U.S. Department of Labor Proposes New (Simpler) Fiduciary Rule Exemption," *Employee Benefits & Executive Compensation and Investment Management Client Alert*
Andrew E. Graw, Megan Monson, Alexander D. Zozos
- > July 2, 2018
"How Regulation A Updates Could Benefit Smaller Reporting Companies," *Corporate Counsel*
John D. "Jack" Hogoboom, Alan Wovsaniker, Alexander Dinur
- > June 5, 2018
"Regulation A Availability for Securities Offerings by Smaller Reporting Companies," *Capital Markets & Securities Client Alert*
Alexander Dinur, Alan Wovsaniker, John D. "Jack" Hogoboom

- > June 12, 2017
"What Can I Find Out About a Company From Its Website?," *Bloomberg Law*
John D. "Jack" Hogoboom, Alexander Dinur

In the Media

- > June 22, 2020
Lowenstein's representation of issuer **Celldex Therapeutics, Inc.** (Celldex) (Nasdaq: CLDX) in connection with the company's approximately \$150 million public offering of common stock is highlighted in the **Global Legal Chronicle**. The Lowenstein team included **Anthony O. Pergola, Alan Wovsaniker, Kate Basmagian, Alexander Dinur, Madeline Roe, Sarah Gore,** and **Robert J. Paradiso**. [View Lowenstein's news announcement about this transaction.](#)
- > January 29, 2020
Lowenstein's representation of **Timber Pharmaceuticals** in its definitive merger agreement with BioPharmX Corporation was noted in **citybizlist, ROI-NJ, BioWorld,** and **Cision PR Newswire**. The Lowenstein deal team included **Steven M. Skolnick, Alan Wovsaniker, Alexander Dinur,** and **Tracy F. Buffer**. [View Lowenstein's news announcement about this transaction.](#)

EDUCATION

- > Northwestern University School of Law (J.D. 2013), cum laude; Senior Editor, *Journal of International Law and Business*
- > Rice University (B.A. 2009), Economics with honors; Trustee Distinguished Scholar; Century Scholar; Economics Honor Society

ADMISSIONS

- > New Jersey
- > Texas